Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 46.5 Billion KRW | -12.77% |
| 2022 | 53.31 Billion KRW | 17.6% |
| 2021 | 45.33 Billion KRW | 0.15% |
| 2020 | 45.26 Billion KRW | -2.88% |
| 2019 | 46.61 Billion KRW | 14.7% |
| 2018 | 40.63 Billion KRW | 35.52% |
| 2017 | 29.98 Billion KRW | -10.14% |
| 2016 | 33.37 Billion KRW | 8.09% |
| 2015 | 30.87 Billion KRW | -0.73% |
| 2014 | 31.09 Billion KRW | -3.93% |
| 2013 | 32.37 Billion KRW | -8.44% |
| 2012 | 35.35 Billion KRW | 6.38% |
| 2011 | 33.23 Billion KRW | 7.94% |
| 2010 | 30.78 Billion KRW | 14.64% |
| 2009 | 26.85 Billion KRW | -0.29% |
| 2008 | 26.93 Billion KRW | -43.33% |
| 2007 | 47.53 Billion KRW | 0.62% |
| 2006 | 47.23 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 12.4 Billion KRW | -4.95% |
| 2024 Q1 | 13.53 Billion KRW | 26.92% |
| 2023 Q1 | 13.81 Billion KRW | 0.9% |
| 2023 Q2 | 12.54 Billion KRW | -9.22% |
| 2023 Q4 | 10.66 Billion KRW | -4.79% |
| 2023 FY | 46.5 Billion KRW | -12.77% |
| 2023 Q3 | 11.2 Billion KRW | -10.67% |
| 2022 Q2 | 13.66 Billion KRW | -2.48% |
| 2022 FY | 53.31 Billion KRW | 17.6% |
| 2022 Q4 | 13.69 Billion KRW | 14.69% |
| 2022 Q1 | 14.01 Billion KRW | 24.49% |
| 2022 Q3 | 11.93 Billion KRW | -12.64% |
| 2021 FY | 45.33 Billion KRW | 0.15% |
| 2021 Q1 | 11.16 Billion KRW | 4.37% |
| 2021 Q2 | 11.39 Billion KRW | 2.05% |
| 2021 Q3 | 11.51 Billion KRW | 1.07% |
| 2021 Q4 | 11.25 Billion KRW | -2.26% |
| 2020 Q1 | 11.18 Billion KRW | -12.78% |
| 2020 Q3 | 12.38 Billion KRW | 12.5% |
| 2020 Q4 | 10.69 Billion KRW | -13.59% |
| 2020 FY | 45.26 Billion KRW | -2.88% |
| 2020 Q2 | 11 Billion KRW | -1.6% |
| 2019 Q1 | 11.46 Billion KRW | 7.57% |
| 2019 Q2 | 11.74 Billion KRW | 2.43% |
| 2019 FY | 46.61 Billion KRW | 14.7% |
| 2019 Q4 | 12.82 Billion KRW | 21.31% |
| 2019 Q3 | 10.57 Billion KRW | -10.02% |
| 2018 Q1 | 10.44 Billion KRW | 0.0% |
| 2018 FY | 40.63 Billion KRW | 35.52% |
| 2018 Q2 | 9.81 Billion KRW | -6.05% |
| 2018 Q4 | 10.66 Billion KRW | 9.67% |
| 2018 Q3 | 9.72 Billion KRW | -0.9% |
| 2017 Q3 | 9.76 Billion KRW | -0.28% |
| 2017 Q1 | 9.76 Billion KRW | 5.81% |
| 2017 FY | 29.98 Billion KRW | -10.14% |
| 2017 Q2 | 9.78 Billion KRW | 0.22% |
| 2016 Q4 | 9.23 Billion KRW | 28.2% |
| 2016 Q1 | 8.33 Billion KRW | -2.59% |
| 2016 FY | 33.37 Billion KRW | 8.09% |
| 2016 Q3 | 7.2 Billion KRW | 0.43% |
| 2016 Q2 | 7.17 Billion KRW | -13.94% |
| 2015 FY | 30.87 Billion KRW | -0.73% |
| 2015 Q4 | 8.55 Billion KRW | 14.9% |
| 2015 Q3 | 7.44 Billion KRW | 13.8% |
| 2015 Q2 | 6.54 Billion KRW | -25.64% |
| 2015 Q1 | 8.79 Billion KRW | 4.52% |
| 2014 Q3 | 8.26 Billion KRW | 46.91% |
| 2014 FY | 31.09 Billion KRW | -3.93% |
| 2014 Q4 | 8.41 Billion KRW | 1.88% |
| 2014 Q1 | 8.63 Billion KRW | 9.08% |
| 2014 Q2 | 5.62 Billion KRW | -34.9% |
| 2013 Q4 | 7.91 Billion KRW | 3.21% |
| 2013 Q1 | 10.11 Billion KRW | 24.47% |
| 2013 Q2 | 8.14 Billion KRW | -19.47% |
| 2013 Q3 | 7.67 Billion KRW | -5.77% |
| 2013 FY | 32.37 Billion KRW | -8.44% |
| 2012 Q3 | 8.43 Billion KRW | -2.79% |
| 2012 Q4 | 8.12 Billion KRW | -3.75% |
| 2012 FY | 35.35 Billion KRW | 6.38% |
| 2012 Q2 | 8.68 Billion KRW | 0.0% |
| 2012 Q1 | - KRW | -100.0% |
| 2011 Q3 | 8.18 Billion KRW | 7.45% |
| 2011 Q2 | 7.61 Billion KRW | -10.96% |
| 2011 FY | 33.23 Billion KRW | 7.94% |
| 2011 Q1 | 8.55 Billion KRW | -3.52% |
| 2011 Q4 | 8.96 Billion KRW | 9.48% |
| 2010 Q4 | 8.86 Billion KRW | 34.01% |
| 2010 Q3 | 6.61 Billion KRW | -1.91% |
| 2010 Q2 | 6.74 Billion KRW | -32.14% |
| 2010 Q1 | 9.94 Billion KRW | 29.87% |
| 2010 FY | 30.78 Billion KRW | 14.64% |
| 2009 Q4 | 7.65 Billion KRW | 40.26% |
| 2009 Q3 | 5.45 Billion KRW | 43.47% |
| 2009 Q1 | 3.03 Billion KRW | -35.01% |
| 2009 Q2 | 3.8 Billion KRW | 25.15% |
| 2009 FY | 26.85 Billion KRW | -0.29% |
| 2008 Q1 | 11.02 Billion KRW | -21.25% |
| 2008 FY | 26.93 Billion KRW | -43.33% |
| 2008 Q4 | 4.67 Billion KRW | -48.93% |
| 2008 Q3 | 9.15 Billion KRW | -8.99% |
| 2008 Q2 | 10.06 Billion KRW | -8.71% |
| 2007 FY | 47.53 Billion KRW | 0.62% |
| 2007 Q2 | 10.96 Billion KRW | 0.0% |
| 2007 Q3 | 11.54 Billion KRW | 5.29% |
| 2007 Q4 | 13.99 Billion KRW | 21.21% |
| 2006 FY | 47.23 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 87.228% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 76.617% |
| HANDOK Inc. | 151.36 Billion KRW | 69.277% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 30.821% |
| Yuhan Corporation | 564.5 Billion KRW | 91.762% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 85.567% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -95.835% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 94.436% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 38.026% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 76.626% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -14.405% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 50.796% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 66.984% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -33.959% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 39.461% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 486.075% |
| JW Holdings Corporation | 446.15 Billion KRW | 89.577% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 77.592% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 92.904% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 86.146% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 40.848% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 38.189% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 35.599% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 74.7% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 84.242% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 93.177% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 86.146% |
| Yuhan Corporation | 564.5 Billion KRW | 91.762% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 76.957% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 34.444% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 53.038% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 86.146% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 68.124% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 73.194% |
| CKD Bio Corp. | 5.01 Billion KRW | -828.189% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 81.708% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 74.743% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 52.607% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 40.848% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 87.482% |
| Boryung Corporation | 333.26 Billion KRW | 86.046% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | 7.074% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 76.626% |
| JW Lifescience Corporation | 51.32 Billion KRW | 9.391% |